

Summary of the Proposed Transaction

Summary in terms of Regulation 13(1A) of the Competition Commission of India (Procedure in regard to the Transaction of Business relating to Combinations) Regulations, 2011 (as amended).

A. Name of the parties to the combination

1. The parties to the transaction are:

(a) Mylan Inc. ("**Mylan**")

(b) Biocon Biologics Limited ("**Biocon Biologics**")¹

(c) Serum Institute Life Sciences Private Limited ("**Serum**")

2. Mylan, Biocon Biologics, and Serum are collectively referred to as the "**Parties**".

B. Nature and purpose of the combination

3. The proposed transaction involves the sale of the global biosimilars portfolio of Viartis Inc. ("**Viartis**") (the indirect parent entity of Mylan) to Biocon Biologics and its subsidiary for cash and stock consideration and acquisition of 1 (one) common equity share and compulsory convertible preference shares convertible into common equity shares, representing at least 12.9% of the fully diluted equity of Biocon Biologics by Mylan (an indirect subsidiary of Viartis) as part consideration for the acquisition of the global biosimilars portfolio of Viartis, in each case, pursuant to the transaction agreement dated February 27, 2022 entered into between Viartis and Biocon Biologics.

¹ Biocon Limited ("**Biocon**") is the parent entity of Biocon Biologics.

4. Prior to closing of the Proposed Transaction, an equity infusion in Biocon Biologics by Biocon and Serum will be carried out for the purpose of funding the acquisition of the global biosimilars portfolio of Viatris by Biocon Biologics and its subsidiary.
5. Accordingly, the proposed transaction is an acquisition within the meaning of Section 5(a) of the Competition Act, 2002. (“Act”).

C. Products, services, and business(es) of the parties to the combination

Mylan

6. Mylan is a Pennsylvania corporation and an indirect wholly owned subsidiary of Viatris. Viatris is a global pharmaceutical company, headquartered in Canonsburg, Pennsylvania, focused on bringing high quality medicines to patients in over 165 countries and territories. It offers a variety of medicines, including brands, generics and biosimilars, and over-the-counter products across the world.

Biocon Biologics

7. Biocon Biologics is a company limited by shares, incorporated in India under the Companies Act, 2013. Biocon Biologics is a subsidiary of Biocon with a focus on Biocon’s biosimilars business. Biocon Biologics is engaged in the manufacturing and commercialization of pharmaceutical formulations such as biosimilars, insulins and drug substances in India. Within India, Biocon Biologics also has a branded formulation business which is responsible for direct B2C sales.

Serum

8. Serum is an Indian private limited company and a subsidiary of Serum Institute of India Private Limited.

D. The respective markets in which the parties to the combination operate

9. The proposed transaction does not result in an appreciable adverse effect on competition in any market in India. Therefore, it is not necessary to define a relevant market. However, in order to aid and assist the Hon'ble Commission in its market assessment, the relevant markets may be delineated as:
- (a) Market for biological drugs based on Trastuzumab including its biosimilars in India.
 - (b) Market for biological drugs based on Bevacizumab including its biosimilars in India.
 - (c) Market for the supply of Fosaprepitant in India.
 - (d) Market for the supply of a combination of Imipenem and Cilastin in India.
 - (e) Market for the supply of Meropenem in India.
 - (f) Market for the supply of Tacrolimus in India.
 - (g) Market for the supply of Teicoplanin in India.
 - (h) Market for the supply of Tacrolimus Ointment and Pimecrolimus in India.
 - (i) Market for the supply of Tigecycline in India.
 - (j) Market for the supply of Everolimus in India.
 - (k) Market for the supply of Mycophenolate Sodium/ Mycophenolate Mofetil in India.
 - (l) Market for the supply of Abiraterone Acetate in India.
 - (m) Market for the supply of a combination of Cefoperazone and Sulbactam in India.
 - (n) Market for the supply of Glimepiride in India.

- (o) Market for the supply of a combination of Glimepiride and Metformin in India.
- (p) Market for the supply of Telmisartan in India.
- (q) Market for the supply of Apremilast in India.
- (r) Market for the supply of Metformin in India.
- (s) Market for the supply of Posaconazole in India.
- (t) Market for the supply of Remdesivir in India.
- (u) Market for the supply of a combination of Telmisartan and Hydrochlorothiazide in India.
- (v) Market for the supply of Favipiravir in India.
- (w) Market for the supply of a combination of Ceftriaxone and Tazobactam in India.
- (x) Market for the supply of Ceftriaxone in India.
- (y) Market for the supply of a combination of Telmisartan and Amlodipine in India.
